IQVIA Holdings Inc.

IQVIA Holdings Inc.

IQV
IQVIA Holdings Inc.US flagNew York Stock Exchange
171.28
USD
+3.47
- -
28.59BMarket Cap
IQVIA Holdings Inc.
IQV
(New York Stock Exchange)

Recent

price

171.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
31.28
34.49
38.78
41.08
42.66
46.63
45.71
44.55
51.11
56.83
59.38
72.49
76.81
81.52
84.97
94.88
97.78
Revenue per Share
1.28
1.93
1.42
1.83
2.79
3.15
0.48
5.86
1.27
0.98
1.46
5.05
5.82
7.39
7.57
7.91
8.14
Basic EPS, GAAP
2.37
0.68
2.11
2.46
2.73
3.23
4.67
2.76
3.9
4.28
7.02
12.03
8.45
8.16
11.66
11.93
12.44
Free Cash Flow per Basic Share
0.54
2.3
4.53
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-7.92
-10.9
-5.37
-5.04
-3.68
68.43
51.97
57.48
61.75
64.67
11.73
75.86
25.54
33.47
43.21
45.28
Book Value per Share
- -
-12.09
-15.42
-11.08
-11.32
-11.57
-55.38
-46.82
-53
-58.48
-60.53
-63.75
-69.17
-72.33
-72.49
-86.96
-88.17
Tangible Book Value per Share
125
125
125
124
128
123
149
218
204
195
191
191
188
184
181
172
170
Basic Weighted Avg Shares
3,924
4,328
4,866
5,100
5,460
5,737
6,815
9,702
10,412
11,088
11,359
13,874
14,410
14,984
15,405
16,310
16,632
Sales/Revenue/Turnover
10.72
8.77
8.53
9.34
10.97
11.82
11.18
7.92
7.77
7.68
6.89
10.18
12.68
13.75
14.73
14.02
13.99
Operating Margin (%)
84
92
98
108
121
128
289
1,011
1,141
1,202
1,287
1,264
1,130
1,125
1,114
1,144
1,167
Depreciation Expense
161
242
178
227
357
387
72
1,277
259
191
279
966
1,091
1,358
1,373
1,360
1,385
Net Income, GAAP
32.09
8.18
34.91
29.7
29.74
29.5
78.12
- -
17.99
32.95
19.3
14.45
19.08
6.92
18.03
15.84
15.66
Effective Tax Rate (%)
4.09
5.59
3.65
4.44
6.54
6.75
1.06
13.16
2.49
1.72
2.46
6.96
7.57
9.06
8.91
8.34
8.33
Profit Margin (%)
- -
173
201
463
674
818
632
398
340
181
532
-478
-597
-895
-1,128
-2,089
-2,109
Working Capital
- -
1,952
2,366
2,036
2,283
2,419
7,108
10,122
10,907
11,941
12,755
12,347
12,859
13,178
13,011
14,109
14,221
LT Debt
- -
-970
-1,359
-667
-704
-336
8,860
8,244
6,954
6,263
6,280
6,042
5,765
6,112
6,067
6,630
6,349
Total Equity
- -
66.45
25.47
26.93
27.6
25.14
1.82
- -
3.63
3.13
3.35
6.38
7.87
9.82
9.18
8.93
9.08
Return on Invested Capital (%)
- -
70.12
26.14
25.8
28.37
23.56
0.89
- -
2.56
1.92
2.35
6.37
6.81
8.66
9.9
9.02
9.04
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
11.87
2.25
1.61
2.29
13.22
13.24
14.35
25.51
20.15
19.76
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,164
1,840
1,844
LT Borrowings
12,793
13,884
13,989
LT Finance Leases
233
225
232
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
170
170
167
Market Capitalization
33,078
38,754
29,009

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
5,979
6,249
6,220
Cash, Cash Equivalents & STI
1,972
2,141
2,103
Accounts Receivable, Net
1,423
1,668
1,632
Inventories
- -
- -
- -
Total Current Liabilities
8,508
8,338
8,329
Payables & Accruals
3,669
2,990
3,811
ST Debt
2,164
1,840
1,844
Deferred Revenue
2,160
2,118
2,261

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-276.3%
1.24%
9.28%
Free Cash Flow
23.22%
14.57%
-2.98%
Net Income, GAAP
181.61%
56.76%
-0.95%
Sales/Revenue/Turnover
11.61%
7.73%
5.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,737
3,814
3,896
3,958
15,405
2025
3,829
4,017
4,100
4,364
16,310
2026
4,151
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.58
1.99
1.57
2.44
7.57
2025
1.42
1.55
1.94
3.02
7.91
2026
1.63
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
IQVIA Holdings Inc operates as a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries. The company offers a comprehensive portfolio including clinical trial services; commercial insights; healthcare intelligence; real-world evidence generation; and advanced data analytics powered by IQVIA Connected Intelligence™, Healthcare-grade AI™, and big data resources. Its technology solutions encompass software platforms for orchestrated customer engagement, data management, and commercial orchestration, supported by partnerships with leading technology providers such as NVIDIA and Veeva Systems. IQVIA's service offerings span drug development, regulatory consulting, market access, and patient centricity solutions, targeting pharmaceutical, biotechnology, and medical device companies worldwide. Headquartered in Durham, North Carolina, and founded through the 2016 merger of Quintiles and IMS Health, IQVIA operates in more than 100 countries with approximately 88,000 employees. Recent company developments include a strategic partnership with NVIDIA to integrate generative and agentic AI within clinical research workflows, accelerating innovation and efficiency in drug development. IQVIA also expanded a clinical and commercial collaboration with Veeva Technologies to enhance interoperability and deliver streamlined solutions for customers in clinical development and commercialization. In 2024 and 2025, IQVIA advanced its healthcare data analytics capabilities through acquisitions of healthcare technology firms, reinforcing its technology portfolio and enabling broader service offerings. Additionally, the company continues to support pharmaceutical product launches globally, tracking and analyzing launch excellence to optimize commercial success across multiple therapeutic areas. IQVIA's ongoing investments in AI and integrated technology ecosystems position it at the forefront of healthcare intelligence and life sciences services innovation.

Company News

APIChatGPT
  • StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertising

  • The Healthcare M&A Wave

  • Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term

  • Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More

  • Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity

  • Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

  • Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain

  • Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain

  • IQVIA (IQV) Up 3.2% Since Last Earnings Report: Can It Continue?

  • IQVIA Holdings Inc. (IQV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

  • IQVIA Announces Offering of Senior Notes

  • Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

  • Veeva vs. IQVIA: Which Life Sciences Tech Stock Holds More Promise?

  • Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now

  • Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

  • IQVIA: The Market May Be Missing The AI & Data Story

  • Artisan Select Equity Fund Q1 2026 Portfolio Update

  • The Broyhill Q1 2026 Portfolio Strategy And Positioning

  • IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term